simvastatin
DrugSubjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.
Other names: zocor
NCT Number: NCT00819403
To determine whether the combination of ezetimibe and simvastatin improves biomarkers of atherothrombosis compared to simvastatin alone in patients with the metabolic syndrome.
Looking for future studies?
Notify Me21 year and older
All sexes
Interventional
Phase 4
Johns Hopkins Hospital, Baltimore, Maryland, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.
Other names: zocor
Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
Other names: vytorin
Time frame: 6 weeks
Measured using whole blood flow cytometry
Time frame: 6 weeks
University of Maryland, Baltimore
Other
The Effects of Ezetimibe/Simvastatin Versus Simvastatin Alone on Platelet and Inflammatory Biomarkers in Patients With the Metabolic Syndrome
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06186102
Arterial Occlusive Diseases, Arteriosclerosis
Aarhus, Jutland, Denmark
View Trial DetailsNCT06460272
Body Weight, Cardiovascular Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT04392284
Body Weight, Cardiovascular Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT04519164
Body Weight, Cardiovascular Diseases
Boston, Massachusetts, United States
View Trial Details